Human beings are big data. We aren’t just 175 pounds of meat and bone. We aren’t just piles of hydrogen and carbon and oxygen. What makes us all different is how it’s all organized and that is information. We can no longer treat people based on simple numbers like weight, pulse, blood pressure, and temperature. What makes us different is much more complicated than that. . . .
→ Read full post: Is Medicine a Big Data Problem?
source: by Timothy Hay
When the Food and Drug Administration told personal-genetics company 23andMe Inc. in November to stop sending consumers detailed information about their DNA, some industry watchers said the move could be a devastating blow to an emerging area of medicine that holds promise for better health outcomes.
But it was more of a flesh wound, said Claremont Creek Ventures Director Ted Driscoll. Though not an investor in 23andMe, he has . . .
→ Read full post: Ted Driscoll’s WSJ interview: 23andMe Flap With FDA Just a Bump in the Road, One Genetics-Testing Investor Says
Our portfolio company Assurex Health just announced the creation of a partnership with Canada’s Center for Addiction and Mental Health (CAMH), one of the world’s leading research centers in the area of addiction and mental health and Canada’s largest mental health teaching hospital. CAMH will offer to Canadian citizens the firm’s pharmacogenomic test, GeneSight, which is now widely available in the US. Claremont Creek Ventures is very excited about this step . . .
→ Read full post: Assurex Health Launches Collaboration with Canadian Mental Health Center
Our portfolio company Assurex Health, announced recently the publication of a groundbreaking analysis of pharmacogenomic data in the International Review of Psychiatry.
The publication strongly validates the premise that the clinical use of genomic testing to help predict patient response to psychiatric medications significantly improves treatment outcomes. This is a key milestone in the continuing discussions within the Psychiatric community about the value of laboratory testing in . . .
→ Read full post: Assurex Health Publishes Seminal Paper on Pharmacogenomics
Thursday June 20, 2013, Atul Butte, MD, PhD, a Stanford University Professor and entrepreneur is being honored at a formal ceremony in the White House Rose Garden in Washington DC. The Obama Administration is honoring Dr. Butte and several other genomics and molecular biology researchers who have focused on making large and complex sets of biological data open and widely accessible to the larger research community. Butte has been a leader . . .
→ Read full post: NuMedii Founder Atul Butte, MD, PhD honored at White House; Claremont Creek Ventures continues investment in health care Big Data.
Congratulations to Claremont Creek portfolio company Natera on closing a $54.6 million financing round. Given Claremont Creek Venture’s involvement since the company’s earliest round of financing, we know Natera is on its way to dominating the market for noninvasive, prenatal genetic testing. The financing is just the latest recent milestone for the company. In February it announced a major agreement with Quest Diagnostics, the world’s leading diagnostic information . . .
→ Read full post: Congratulations to Natera on Completing $54.6 Million Financing to Support Expansion
The human genome evolved for us as Paleolithic cavemen, arming us to cope with leopards, communicable diseases, infections, parasites and starvation. But modern society has succeeded in taming most of those risks, and now, ironically, our biggest health challenges are largely a byproduct of our success. As we extend our lifespan, cancer and cardiac disease increase in incidence. We confront an epidemic of diabetes and obesity related diseases largely caused by overconsumption and inactivity. Our genome never evolved to benefit obese 70 year olds. Cavemen didn’t typically live past 40 and didn’t drink high-fructose corn syrup in Big Gulps. . . .
→ Read full post: The Golden Age of Healthcare Investing is Now
Congratulations to Natera—our portfolio company who is the leading innovator in prenatal genetic testing! Yesterday they announced a major deal with Quest Diagnostics (NYSE: DGX), the world’s leading diagnostic information services company. Quest Diagnostics will offer physicians access to Panorama™, the new non-invasive prenatal test developed by Natera. (Read the Quest Press Release)
Panorama uses free-floating fetal DNA in circulating maternal blood to screen for chromosomal abnormalities associated with . . .
→ Read full post: Congratulations: Quest Diagnostics to offer access to Natera’s Panorama, non-invasive prenatal test
February 20, 2013 source: the original post by Ed Silverman appeared in Pharmalot
As drug development and diagnostics increasingly converge, the advent of personalized medicine is increasing all the time. Of course, we are not quite there yet, but the advent of electronic medical records and the genome are inching us closer all the time. But this poses challenges, of course, and Ted Driscoll, who heads the digital healthcare team at . . .
→ Read full post: Ted Driscoll featured in Pharmalot, Op-Ed: Entering The Golden Age Of Big Data
Bloomberg reporter Ryan Flinn recently wrote an article on Brain Scans Seek Best Drug Match for Depression Patients. The article summarizes some of the technologies that are being used by clinicians to assist in diagnosis and treatment of depression, and focused on technologies provided by two companies. The first company profiled uses a technology that matches EEGs – brain waves – to a database of matched EEG/depression scores, and the second uses a . . .
→ Read full post: AssureRx: advanced genomics tools inform patient response to psychotropic therapy